Revolution Medicines, Inc. (RVMD)
| Market Cap | 46.30B +581.9% |
| Revenue (ttm) | n/a |
| Net Income | -1.77B |
| EPS | -8.92 |
| Shares Out | 214.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,649,694 |
| Open | 209.15 |
| Previous Close | 212.00 |
| Day's Range | 209.09 - 216.72 |
| 52-Week Range | 35.42 - 216.72 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 221.90 (+2.73%) |
| Earnings Date | Aug 5, 2026 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $221.9, which is an increase of 2.73% from the latest price.
News
Revolution Medicines price target raised to $231 from $210 at Truist
Truist raised the firm’s price target on Revolution Medicines (RVMD) to $231 from $210 and keeps a Buy rating on the shares. The firm is increasing its estimates to reflect…
Revolution Medicines price target raised to $220 from $165 at Wolfe Research
Wolfe Research analyst Kalpit Patel raised the firm’s price target on Revolution Medicines (RVMD) to $220 from $165 and keeps an Outperform rating on the shares. Given “good progress” on…
BeOne Medicines partners with Revolution Medicines for clinical development
BeOne Medicines (ONC) and Revolution Medicines (RVMD) announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncolog...
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nas...
Revolution Medicines price target raised to $227 from $205 at JPMorgan
JPMorgan raised the firm’s price target on Revolution Medicines (RVMD) to $227 from $205 and keeps an Overweight rating on the shares following the Q2 results from earlier this week.
Revolution Medicines price target raised to $230 from $220 at Evercore ISI
Evercore ISI raised the firm’s price target on Revolution Medicines (RVMD) to $230 from $220 and keeps an Outperform rating on the shares.
Revolution Medicines price target raised to $201 from $192.10 at Wedbush
Wedbush raised the firm’s price target on Revolution Medicines (RVMD) to $201 from $192.10 and keeps an Outperform rating on the shares after the company reported Q2 financials and provided…
Revolution Medicines price target raised to $230 from $195 at Oppenheimer
Oppenheimer raised the firm’s price target on Revolution Medicines (RVMD) to $230 from $195 and keeps an Outperform rating on the shares. The firm views Revolution Medicines’ Q2 update as…
Revolution Medicines price target raised to $203 from $182 at RBC Capital
RBC Capital raised the firm’s price target on Revolution Medicines (RVMD) to $203 from $182 and keeps an Outperform rating on the shares.
Revolution Medicines price target raised to $240 from $235 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $240 from $235 and keeps a Buy rating on the shares after the company announced Q2…
Revolution Medicines reports Q2 EPS ($3.06), consensus ($2.06)
“This has been a transformational period for Revolution Medicines (RVMD), as we rapidly translated unprecedented Phase 3 results for daraxonrasib into an active Expanded Access Program and the filing ...
Revolution Medicines Earnings Call Transcript: Q2 2026
Q2 2026 saw transformational clinical and regulatory progress, with daraxonrasib showing paradigm-shifting results in pancreatic cancer and rapid expansion of access programs. Financially, strong liquidity supports increased investment in manufacturing, clinical, and commercial readiness, while pivotal trials advance in pancreatic and lung cancer.
Revolution Medicines Earnings release: Q2 2026
Revolution Medicines released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Revolution Medicines Quarterly report: Q2 2026
Revolution Medicines has published its Q2 2026 quarterly earnings report on August 5, 2026.
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
REDWOOD CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines Slides: Corporate presentation
Revolution Medicines has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines price target raised to $192.10 from $181 at Wedbush
Wedbush analyst Robert Driscoll raised the firm’s price target on Revolution Medicines (RVMD) to $192.10 from $181 and keeps an Outperform rating on the shares. The firm notes the company…
Revolution Medicines receives FDA review acceptance for daraxonrasib
Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration accepted for review the company’s new drug application for daraxonrasib for previously treated metastatic pancreatic du...
Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Tango Therapeutics price target raised to $40 from $36 at Mizuho
Mizuho raised the firm’s price target on Tango Therapeutics (TNGX) to $40 from $36 and keeps an Outperform rating on the shares. The firm believes Revolution Medicines’ (RVMD) data for…
Revolution Medicines price target raised to $235 from $205 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $235 from $205 and keeps a Buy rating on the shares. The outlook for Revolution Medicines’…
EMA accelerates assessment of Revolution Medicines daraxonrasib
Revolution Medicines (RVMD) announced that European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has started a phased review of data on daraxonrasib, the company’s inves...
European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.